- Title: Subtitle
- Prognostic Factors for Adult Burkitt Lymphoma Patients Treated with Dose-Adjusted EPOCH-R
- Creators
- Rahul Lakhotia - National Institutes of HealthKieron Dunleavy - Georgetown UniversityJeremy S. Abramson - Massachusetts General HospitalBrian K. Link - University of IowaBayard L. Powell - Atrium Health Wake Forest BaptistChristopher Melani - National Institutes of HealthNicole Lucas - Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MDSeth M. Steinberg - National Cancer InstituteJonathan W. Friedberg - University of RochesterBrad S. Kahl - Washington University in St. LouisRichard F. Little - National Cancer InstituteNancy L. Bartlett - Washington University in St. LouisAriela Noy - Memorial Sloan Kettering Cancer CenterWyndham H. Wilson - National Cancer InstituteMark Roschewski - National Cancer Institute
- Resource Type
- Letter/Communication
- Publication Details
- Blood advances, Vol.7(18), pp.5320-5324
- DOI
- 10.1182/bloodadvances.2023010223
- PMID
- 37389844
- PMCID
- PMC10506053
- NLM abbreviation
- Blood Adv
- ISSN
- 2473-9529
- eISSN
- 2473-9537
- Publisher
- Elsevier Inc
- Language
- English
- Electronic publication date
- 06/30/2023
- Date published
- 09/14/2023
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984444127402771
Letter/Communication
Prognostic Factors for Adult Burkitt Lymphoma Patients Treated with Dose-Adjusted EPOCH-R
Blood advances, Vol.7(18), pp.5320-5324
09/14/2023
DOI: 10.1182/bloodadvances.2023010223
PMCID: PMC10506053
PMID: 37389844
Abstract
Details
Metrics
12 Record Views